Cancer mortality in Europe, 1995–1999, and an overvi

International Journal of Cancer 110, 155-169

DOI: 10.1002/ijc.20097

Citation Report

#	Article	IF	CITATIONS
1	Trends in cancer mortality in the European Union and accession countries, 1980–2000. Annals of Oncology, 2004, 15, 1425-1431.	1.2	54
2	Declining mortality from kidney cancer in Europe. Annals of Oncology, 2004, 15, 1130-1135.	1.2	30
3	The role of chemoradiotherapy in the treatment of stage III non-small-cell lung cancer. Annals of Oncology, 2004, 15, iv71-iv80.	1.2	4
4	Trends in cancer mortality in Mexico, 1970–1999. Annals of Oncology, 2004, 15, 1712-1718.	1.2	25
5	Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer, 2004, 101, 2843-2850.	4.1	111
6	Management of small cell lung cancer. European Journal of Cancer, Supplement, 2004, 2, 40-43.	2.2	0
9	Trends in incidence of various morphologies of malignant melanoma in Vaud and Neuch??tel, Switzerland. Melanoma Research, 2005, 15, 73-75.	1.2	27
10	Monitoring the decrease in breast cancer mortality in Europe. European Journal of Cancer Prevention, 2005, 14, 497-502.	1.3	105
11	Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood, 2005, 105, 4569-4572.	1.4	221
12	Role of fried foods and oral/pharyngeal and oesophageal cancers. British Journal of Cancer, 2005, 92, 2065-2069.	6.4	30
13	Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. British Journal of Cancer, 2005, 92, 2171-2180.	6.4	163
14	The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Gynecologic Oncology, 2005, 99, 552-556.	1.4	24
15	Trends in colorectal cancer mortality in Japan, 1970-2000. International Journal of Cancer, 2005, 113, 339-341.	5.1	17
16	Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias. Cancer, 2005, 104, 439-440.	4.1	0
19	Multiple soft tissue sarcomas. Cancer, 2005, 104, 440-441.	4.1	7
20	Incidence of multiple myeloma in Olmsted County, Minnesota. Cancer, 2005, 104, 442-442.	4.1	7
21	Hormone replacement therapy and colorectal cancer: an update. The Journal of the British Menopause Society, 2005, 11, 166-172.	1.3	36
22	Biological characterization of ovarian cancer: prognostic and therapeutic implications. Annals of Oncology, 2005, 16, iv95-iv101.	1.2	25

#	Article	IF	CITATIONS
23	Lung cancer mortality in European women: recent trends and perspectives. Annals of Oncology, 2005, 16, 1597-1604.	1.2	69
24	Adjuvant chemotherapy of gastric cancer: which regimens?. Annals of Oncology, 2005, 16, iv102-iv105.	1.2	2
25	Genotoxicity of Nicotine in Mini-Organ Cultures of Human Upper Aerodigestive Tract Epithelia. Toxicological Sciences, 2005, 88, 134-141.	3.1	34
26	Hepatocellular Carcinoma: Epidemiology, Risk Factors, and Screening. Seminars in Liver Disease, 2005, 25, 143-154.	3.6	368
27	Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo. British Journal of Cancer, 2005, 92, 1084-1088.	6.4	52
28	The use of denial in an ethnically diverse British cancer population: a cross-sectional study. British Journal of Cancer, 2005, 92, 1393-1397.	6.4	31
29	Trends in cancer mortality in the Americas, 1970–2000. Annals of Oncology, 2005, 16, 489-511.	1.2	133
30	Management of small-cell lung cancer. Annals of Oncology, 2005, 16, ii235-ii239.	1.2	35
31	Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. International Journal of Oncology, 2005, 26, 95.	3.3	3
32	Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. International Journal of Oncology, 2005, 27, 481.	3.3	14
33	Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis, 2005, 20, 381-385.	2.6	17
34	Noncontraceptive health benefits of combined oral contraception. Human Reproduction Update, 2005, 11, 513-525.	10.8	99
35	Converging patterns of colorectal cancer mortality in Europe. European Journal of Cancer, 2005, 41, 430-437.	2.8	50
36	Morbidity and mortality rates following gastric cancer surgery and contiguous organ removal, a population based study. European Journal of Surgical Oncology, 2005, 31, 1141-1144.	1.0	23
37	Mutation Scanning of the P53 Tumor Supressor Gene in Renal and Liver Transplant Patients in Hungary. Transplantation Proceedings, 2005, 37, 969-972.	0.6	4
38	Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease, 2005, 9, 191-211.	2.1	826
39	The Role of Surgery in Stage IIIA Non–Small Cell Lung Cancer. Hematology/Oncology Clinics of North America, 2005, 19, 303-319.	2,2	3
40	The Long-Term Evolution of Quality of Life for Disease-Free Breast Cancer Survivors. Journal of Psychosocial Oncology, 2006, 24, 89-123.	1.2	27

#	ARTICLE	IF	Citations
41	Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet Journal of Rare Diseases, 2006, 1, 44.	2.7	18
42	Mechanisms of Disease: the epidemiology of bladder cancer. Nature Reviews Urology, 2006, 3, 327-340.	1.4	212
43	Targeted kinase inhibitors in lung cancer: From EGFR to patients. European Journal of Cancer, 2006, 42, 124-125.	2.8	0
44	Familial risks and temporal incidence trends of multiple myeloma. European Journal of Cancer, 2006, 42, 1661-1670.	2.8	73
45	Estimating regional cancer burden in countries with partial registration coverage: An application to all malignant neoplasms in Italy over the period 1970–2010. European Journal of Cancer, 2006, 42, 3236-3245.	2.8	19
46	Oral contraceptives and ovarian cancer: an update, 1998–2004. European Journal of Cancer Prevention, 2006, 15, 117-124.	1.3	49
47	Trends in cancer mortality in Switzerland, 1980–2001. European Journal of Cancer Prevention, 2006, 15, 1-9.	1.3	12
48	Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. Melanoma Research, 2006, 16, 453-457.	1.2	24
49	Radiofrequency Ablation in Patients With Primary and Secondary Hepatic Malignancies. Journal of Gastrointestinal Surgery, 2006, 10, 960-973.	1.7	39
50	Clinical experience with docetaxel for Chinese breast cancer patients: Hematological toxicity profiles. Breast Cancer, 2006, 13, 192-196.	2.9	6
51	Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes and Control, 2006, 17, 871-888.	1.8	108
52	The beginning of the tobacco-related lung-cancer epidemic among Spanish women. International Journal of Cancer, 2006, 118, 1063-1064.	5.1	3
53	Trends in laryngeal cancer mortality in Europe. International Journal of Cancer, 2006, 119, 673-681.	5.1	34
54	Tobacco smoking, alcohol drinking and non-Hodgkin's lymphoma: A European multicenter case-control study (Epilymph). International Journal of Cancer, 2006, 119, 901-908.	5.1	75
55	Time trends of breast cancer survival in Europe in relation to incidence and mortality. International Journal of Cancer, 2006, 119, 2417-2422.	5.1	95
56	Epidemiology of Lung Cancer. , 2006, , 3-12.		0
57	Smoking, healthcare cost, and loss of productivity in Sweden 2001. Scandinavian Journal of Public Health, 2007, 35, 187-196.	2.3	24
58	Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer, 2007, 14, 81-90.	3.1	56

#	Article	IF	CITATIONS
59	Is there a link between diet and esophageal cancer?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 2-3.	1.7	16
60	Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Annals of Oncology, 2007, 18, vi120-vi123.	1.2	50
61	Burden of cervical cancer in Europe: estimates for 2004. Annals of Oncology, 2007, 18, 1708-1715.	1.2	110
62	Specific Features of Non-small Cell Lung Cancer in Women: A Retrospective Study of 1738 Cases Diagnosed in Bas-Rhin between 1982 and 1997. Journal of Thoracic Oncology, 2007, 2, 466-474.	1.1	48
63	A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respiratory Research, 2007, 8, 43.	3.6	19
64	Opinion of the scientific panel on contaminants in the food chain [CONTAM] related to the potential increase of consumer health risk by a possible increase of the existing maximum levels for aflatoxins in almonds, hazelnuts and pistachios and derived prod. EFSA Journal, 2007, 5, 446.	1.8	92
65	Regional Estimates of Breast Cancer Burden in Italy. Tumori, 2007, 93, 374-379.	1.1	26
66	Regional Estimates of all Cancer Malignancies in Italy. Tumori, 2007, 93, 345-351.	1.1	31
68	Trends in lung cancer among young European women: The rising epidemic in France and Spain. International Journal of Cancer, 2007, 121, 462-465.	5.1	61
69	Trends in oesophageal cancer incidence and mortality in Europe. International Journal of Cancer, 2008, 122, 1118-1129.	5.1	199
70	Declining mortality from bladder cancer in Europe. BJU International, 2008, 101, 11-19.	2.5	80
71	Epidemiology of urinary bladder cancer: from tumor development to patient's death. World Journal of Urology, 2007, 25, 285-295.	2.2	221
72	4-Hydroxy-1-(3-pyridyl)-1-butanone-releasing DNA adducts in lung, lower esophagus and cardia of sudden death victims. Toxicology, 2008, 245, 154-161.	4.2	35
73	On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes and Control, 2008, 19, 97-106.	1.8	64
74	Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunology, Immunotherapy, 2008, 57, 97-106.	4.2	105
75	Incidence and mortality from nonâ€Hodgkin lymphoma in Europe: The end of an epidemic?. International Journal of Cancer, 2008, 123, 1917-1923.	5.1	76
76	Trends in mortality from hepatocellular carcinoma in Europe, 1980â€2004. Hepatology, 2008, 48, 137-145.	7.3	235
77	Protective role of curcumin against nicotine-induced genotoxicity on rat liver under restricted dietary protein. European Journal of Pharmacology, 2008, 588, 151-157.	3.5	33

#	Article	IF	CITATIONS
80	Risks of Neoadjuvant Chemotherapy and Radiation Therapy. Thoracic Surgery Clinics, 2008, 18, 71-80.	1.0	22
81	Non-contraceptive benefits of oral contraceptives. Expert Opinion on Pharmacotherapy, 2008, 9, 2317-2325.	1.8	31
82	The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival. Clinical Cancer Research, 2008, 14, 5833-5839.	7.0	32
83	Cancer mortality in the European Union, 1970–2003, with a joinpoint analysis. Annals of Oncology, 2008, 19, 631-640.	1.2	133
84	Tobacco Smoking, Smoking Cessation, and Cumulative Risk of Upper Aerodigestive Tract Cancers. American Journal of Epidemiology, 2008, 167, 468-473.	3.4	64
85	Time trends in incidence and prognosis of primary liver cancer and liver metastases of unknown origin in a Danish region, 1985–2004. European Journal of Gastroenterology and Hepatology, 2008, 20, 104-110.	1.6	21
86	Cancer Mortality in Italy, 1970–2002. Tumori, 2008, 94, 640-657.	1.1	14
88	Diferenças de gênero na tendência de mortalidade por câncer de pulmão nas macrorregiÃμes brasileiras. Revista Brasileira De Epidemiologia, 2008, 11, 411-419.	0.8	7
89	Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Human Reproduction Update, 2009, 15, 489-498.	10.8	99
90	Perspectives in Adjuvant Therapy of Gastric Cancer. Oncology, 2009, 77, 38-42.	1.9	17
91	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics, 2009, 18, 1869-1878.	2.9	17
92	Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma. Clinical Cancer Research, 2009, 15, 4875-4884.	7.0	42
93	Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil. International Journal of Clinical Oncology, 2009, 14, 326-331.	2.2	6
94	Effective diameter of balloon dilation for benign esophagojejunal anastomotic stricture after total gastrectomy. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 1775-1780.	2.4	11
95	Trends in cancer mortality among migrants in England and Wales, 1979–2003. European Journal of Cancer, 2009, 45, 2168-2179.	2.8	28
96	Liver Function as Assessed by Breath Tests in Patients With Hepatocellular Carcinoma. Journal of Surgical Research, 2009, 157, 199-207.	1.6	23
97	Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models. Molecular Cancer, 2009, 8, 78.	19.2	10
99	CLIC4 mediates TGF- \hat{l}^21 -induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer. Oncology Reports, 2009, 22, 541-8.	2.6	63

#	Article	IF	CITATIONS
100	Trends in cancer mortality in Brazil, 1980–2004. European Journal of Cancer Prevention, 2010, 19, 79-86.	1.3	51
102	Age–period–cohort analysis of colorectal cancer in East Anglia, 1971–2005. Cancer Epidemiology, 2010, 34, 232-237.	1.9	6
103	Interleukin 8 (IL-8) - a universal biomarker?. International Archive of Medicine, 2010, 3, 11.	1.2	94
104	Hepatitis C and hepatocellular carcinoma. Annals of Hepatology, 2010, 9, S119-S122.	1.5	33
105	Cervical, Uterine Corpus, and Ovarian Cancer Mortality in Greece During 1980 to 2005. International Journal of Gynecological Cancer, 2010, 20, 482-487.	2.5	1
106	Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic. Mayo Clinic Proceedings, 2010, 85, 225-230.	3.0	113
107	Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Annals of Oncology, 2010, 21, 1323-1360.	1.2	340
108	An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics. International Journal of Molecular Sciences, 2010, 11, 4826-4842.	4.1	20
110	Managing multiple myeloma in the elderly: are we making progress?. Expert Review of Hematology, 2011, 4, 301-315.	2.2	6
111	Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. European Journal of Cancer, 2011, 47, 1420-1431.	2.8	18
112	Cancer mortality trend analysis in Italy, 1970–2007. European Journal of Cancer Prevention, 2011, 20, 364-374.	1.3	32
113	Involvement of MAPK Phosphatase-1 in Dexamethasone-Induced Chemoresistance in Lung Cancer. Journal of Chemotherapy, 2011, 23, 221-226.	1.5	8
114	Non-Viral Causes of Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2011, 42, 191-194.	1.3	11
115	Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies. Clinical Cancer Research, 2011, 17, 4451-4461.	7.0	56
116	Cancer epidemiology in Central and South Eastern European countries. Croatian Medical Journal, 2011, 52, 478-487.	0.7	53
117	A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Annals of Oncology, 2012, 23, 287-297.	1.2	82
118	Loss of the Integrin-Activating Transmembrane Protein Fam38A (Piezo1) Promotes a Switch to a Reduced Integrin-Dependent Mode of Cell Migration. PLoS ONE, 2012, 7, e40346.	2.5	133
119	Temporal and geographic variations of Waldenstrom macroglobulinemia incidence. Cancer, 2012, 118, 3793-3800.	4.1	104

#	Article	IF	Citations
120	Management of Lung Cancer in Older People. , 2013, , .		1
121	Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation. Toxicology Letters, 2013, 221, 73-82.	0.8	32
122	A birth cohort analysis of the incidence of ascending and descending colon cancer in the United States, 1973–2008. Cancer Causes and Control, 2013, 24, 1147-1156.	1.8	8
123	Incidence and mortality trends of head and neck cancer in Croatia in the period 1988–2008. Acta Oto-Laryngologica, 2013, 133, 305-312.	0.9	9
125	Pancreatic cancer mortality in Serbia from 1991-2010 $\hat{a} \in$ a joinpoint analysis. Croatian Medical Journal, 2013, 54, 369-375.	0.7	9
126	Epidemiology of myeloma. , 0, , 1-10.		0
127	The C-Terminal Fragment of Prostate-Specific Antigen, a 2331 Da Peptide, as a New Urinary Pathognomonic Biomarker Candidate for Diagnosing Prostate Cancer. PLoS ONE, 2014, 9, e107234.	2.5	12
128	Putative Surrogate Biomarkers to Predict Patients with Acquired Platinum Resistance in Ovarian Cancer. Journal of Molecular Biomarkers & Diagnosis, 2014, 05, .	0.4	0
129	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	107
130	Trends in major cancer mortality in Korea, 1983–2012, with a joinpoint analysis. Cancer Epidemiology, 2015, 39, 939-946.	1.9	35
131	Intact PTEN Expression by Immunohistochemistry is Associated With Decreased Survival in Advanced Stage Ovarian/Primary Peritoneal High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2015, 34, 497-506.	1.4	11
132	Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial. Pathology and Oncology Research, 2015, 21, 775-782.	1.9	8
133	Convergence with SEER database achieved by a breast cancer network: a longitudinal benchmark of 5-year relative survival. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1109-1118.	2.5	1
134	Laryngeal cancer mortality trends in <scp>E</scp> uropean countries. International Journal of Cancer, 2016, 138, 833-842.	5.1	49
135	A Rare Cause of Mechanical Intestinal Obstruction: A Neoplastic Intra-Abdominal Testis. International Surgery, 2016, 101, 167-170.	0.1	1
136	Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer, 2016, 16, 205.	2.6	5
137	Trends in site- and sex-specific cancer mortality between 1979 and 2010 in Belgium compared with Europe using WHO data. Journal of Public Health, 2016, 38, e68-e76.	1.8	5
138	Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe. Expert Opinion on Pharmacotherapy, 2016, 17, 93-104.	1.8	3

#	Article	IF	CITATIONS
139	From rare to common and back again: 60years of lysosomal dysfunction. Molecular Genetics and Metabolism, 2016, 117, 53-65.	1.1	17
140	Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis. Journal of Skin Cancer, 2017, 2017, 1-16.	1.2	6
142	The Validity and Reliability of Health Belief Scale for Testicular Cancer Self-Examination. American Journal of Men's Health, 2018, 12, 531-538.	1.6	20
143	Trends in Mortality Rates for Gastrointestinal Cancers in Fars Province, Iran (2005–2015). Journal of Gastrointestinal Cancer, 2020, 51, 63-69.	1.3	15
144	Extended Analysis and Evidence Integration of Chloroprene as a Human Carcinogen. Risk Analysis, 2020, 40, 294-318.	2.7	4
145	Premature mortality of gastrointestinal cancer in Iran: trends and projections 2001–2030. BMC Cancer, 2020, 20, 752.	2.6	5
146	Aspirin and Cancer Risk: A Summary Review to 2007. Recent Results in Cancer Research, 2009, 181, 231-251.	1.8	50
147	Geographical Disparities in Mortality Rates: Spatial Data Mining and Bayesian Hierarchical Modeling. Contributions To Statistics, 2013, , 1-29.	0.2	1
148	Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers. PLoS Medicine, 2009, 6, e1000025.	8.4	35
149	Tendencia de la mortalidad por cáncer en Argentina, Cuba y Uruguay en un perÃodo de 15 años. Revista Cubana De Salud Publica, 2010, 36, 115-125.	0.0	11
150	Cancer mortality in Latin America: implications for prevention. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2005, 18, 1-4.	1,1	10
151	An 18-year study of thyroid carcinoma in the western region of Saudi Arabia: a retrospective single-center study in a community hospital. Annals of Saudi Medicine, 2018, 38, 336-343.	1.1	8
152	Hormone Replacement Therapy in Menopause and Breast, Colorectal, and Lung Cancer: An Update., 2007,, 599-608.		0
154	Metabolic Disease and Hepatocellular Carcinoma. , 2009, , 283-307.		0
156	A study on clinicopathological characteristics of ovarian masses. Korean Journal of Obstetrics and Gynecology, 2010, 53, 235.	0.1	0
157	Mortalidad por cáncer en Cuba. Revista Cubana De Salud Publica, 2010, 36, .	0.0	5
158	Clinical Epidemiology and the Impact of Comorbidity on Treatment and Outcome., 2013,, 13-30.		0
159	Metabolic Disease and Hepatocellular Carcinoma. , 2016, , 287-301.		0

#	Article	IF	CITATIONS
160	ears of life lost due to bladder cancer among the inhabitants of Poland in the years 2000 to 2014. Central European Journal of Urology, 2017, 70, 338-343.	0.3	2
163	COMMENTARY: WELL-BEING IN VERY OLD AGE: OLD AND NEW ISSUES. , 2006, , 131-134.		0
164	Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer. International Journal of Hematology-Oncology and Stem Cell Research, 2013, 7, 24-8.	0.3	5
165	Mortality trends of gastrointestinal cancers in Iranian population. Gastroenterology and Hepatology From Bed To Bench, 2013, 6, S52-7.	0.6	30
166	Hepatocellular carcinoma in the world and the middle East. Middle East Journal of Digestive Diseases, 2010, 2, 31-41.	0.4	36
168	Investigation of knowledge, attitude and behaviors of university students on testicular cancer: results from two different cities. The European Research Journal, 0, , .	0.3	0
170	Disease burden, risk factors, and temporal trends of eye cancer: A global analysis of cancer registries. Clinical and Experimental Ophthalmology, 0, , .	2.6	0